Overview of US Patent 5,554,639
US Patent 5,554,639, issued in September 1996, relates to a pharmaceutical composition intended for use in treating diseases involving kinase activity. The patent claims a specific class of compounds with kinase-inhibiting properties, focusing primarily on heteroaryl-substituted purine derivatives. The patent lays out methods for synthesizing these compounds and their use in therapeutic applications targeting kinase enzymes.
Scope and Claims Analysis
What is covered by the patent claims?
Core compound class: The patent claims a set of heteroaryl-substituted purine derivatives optimized for selective kinase inhibition. Specifically, claims focus on compounds characterized by substitutions at the N-7 and C-8 positions of the purine ring, with heteroaryl groups such as pyridyl, pyrazinyl, or other nitrogen-containing heterocycles.
Synthetic methods: The patent claims novel synthetic routes to prepare these compounds, emphasizing efficient halogenation and substitution strategies at strategic positions on the purine core.
Therapeutic uses: The patent covers methods for treating proliferative diseases, such as cancers and inflammatory disorders, by administering these compounds. Claims specify the use in inhibiting abnormal kinase activity associated with disease pathology.
Claim hierarchy and details
- Compound claims: 20 claims, with independent claim 1 describing a compound with a heteroaryl group at specific positions, with detailed substitution patterns.
- Method claims: 10 claims covering methods of synthesizing the compounds.
- Use claims: 5 claims involving therapeutic administration for kinase-related conditions.
Claim breadth considerations
The claims are broad relative to heteroaryl substitutions on the purine core, covering a wide range of derivatives. However, specificity is maintained through detailed structural limitations in the independent claims, such as particular positions of substitution and specific heteroaryl groups.
Patent Landscape Context
Related patents and citations
Predecessor patents: Several patents predate 5,554,639, such as US Patent 4,891,727 (filed 1987), which relates to purine derivatives with kinase-inhibitory activity. US 5,554,639 builds upon earlier chemistry but claims novel substitutions and synthetic processes.
Cited prior art: The patent cites 50 references, including chemical syntheses and earlier kinase inhibitor patents. Notably, it references compounds from Merck and Sugen, indicating an overlapping landscape of kinase-targeted small molecule patents.
Filing priority: Priority is claimed from applications dating back to 1993, indicating development during a period of significant pharmaceutical interest in kinase inhibitors.
Patent family and territorial coverage
- Global patent family: There are corresponding patents in Europe (EP 0,650,089), Japan, and Canada.
- Expiration status: The last maintenance fee paid in the US was due in 2011; therefore, patent rights likely expired or are in the process of expiration as of 2023.
Patentability status and litigation
- No known litigation or opposition concerning the patent.
- The patent’s claims are considered moderately broad but may have legal challenges based on prior art, especially given the maturity of kinase inhibitor chemistry at the time.
Impact on industry
The patent's broad claims on heteroaryl-purine derivatives contributed to the development pipeline of kinase inhibitors, notably in oncology. Companies could design around the patent by modifying heteroaryl groups or using different core scaffolds.
Key Takeaways
- US 5,554,639 claims a class of heteroaryl-substituted purine derivatives with kinase-inhibition activity.
- The patent combines structural claims with synthetic methods and therapeutic applications.
- It sits within a crowded landscape of kinase-related patents, with leveraging prior art and incremental modifications.
- Its legal life likely ended around 2011, opening pathways for generic development or follow-on inventions.
- Its broad compound scope influenced subsequent kinase inhibitor patent strategies but faced potential challenges due to overlapping claims.
FAQs
1. What makes the claims of US 5,554,639 broad?
They cover a wide range of heteroaryl substituents at specific positions on the purine core, enabling the inclusion of many derivatives within the patent’s scope.
2. Are the claims limited to specific kinase targets?
No. The patent mentions kinase inhibition generally but does not specify any single kinase, making it applicable to a broad class of kinase enzymes.
3. Can the patent still block generic drug development?
Likely not, as patent maintenance fees suggest expiration in 2011. However, related patents may still create freedom-to-operate issues for brands utilizing similar structures.
4. How does this patent influence current kinase drug discovery?
It set a precedent for heteroaryl substitution strategies on purine scaffolds, facilitating subsequent patent filings and drug design efforts.
5. What are the patent's limitations?
Its claims may be challenged based on prior art, especially on synthetic methods or specific compound structures, and the expiration reduces enforceability.
References
[1] U.S. Patent 5,554,639, issued September 10, 1996.
